Evidence map›Paper›PMID 35302390›Full record

ArticleAIDS research and human retroviruses2022

Molecular Characterization of the

Ramesh Karunaianantham, Manohar Nesa Kumar, Bindu Gopalan, Hemalatha Haribabu, Luke Elizabeth Hanna, G N Sanjeeva, Devarajulu Reddy, Anita Shet, Soumya Swaminathan, Chandrasekaran Padmapriyadarsini

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Ramesh KarunaiananthamICMR-National Institute for Research in Tuberculosis, Chennai, India.
Manohar Nesa KumarICMR-National Institute for Research in Tuberculosis, Chennai, India.
Bindu GopalanDivision of Microbiology/Infectious Diseases Unit, St. Johns Research Institute, Bangalore, India.
Hemalatha HaribabuICMR-National Institute for Research in Tuberculosis, Chennai, India.
Luke Elizabeth HannaICMR-National Institute for Research in Tuberculosis, Chennai, India.
G N SanjeevaDepartment of Pediatrics, Indira Gandhi Institute of Child Health, Bangalore, India.
Devarajulu ReddyICMR-National Institute for Research in Tuberculosis, Chennai, India.
Anita ShetDivision of Microbiology/Infectious Diseases Unit, St. Johns Research Institute, Bangalore, India.
Soumya SwaminathanICMR-National Institute for Research in Tuberculosis, Chennai, India.
Chandrasekaran PadmapriyadarsiniICMR-National Institute for Research in Tuberculosis, Chennai, India.ORCID 0000-0002-1324-4595
National Institute of Research in Tuberculosis · INIndira Gandhi Institute of Child Health · INJohns Hopkins University · USSt. Johns Hospital · IEWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

HIV-1

Indexed as

Anti-HIV AgentsGenes, polHIV-1HIV InfectionsHIV SeropositivityChildDrug Resistance, ViralGenotypeHumansInfectious Disease Transmission, VerticalMutationPhylogenyPyridazinesReverse Transcriptase InhibitorsRilpivirineAnti-HIV AgentsPyridazinesReverse Transcriptase InhibitorsRilpivirineHIV-1 drug resistanceHIV-1 pol geneHIV-1 subtype CSouth Indiavertical transmissionvirological failure

Identifiers

PMID35302390
PMCPMC9225826
OpenAlexW4220657042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.